2019 Annual Conference   |   January 30 - February 1, 2019   |   Salt Lake City, Utah, USA

Conference Chairs
Lewis Roberts, MB, ChB, PhD
Lewis Roberts, MB, ChB, PhD
Jennifer Knox, MD, MSc, FRCPC
Jennifer Knox, MD, MSc, FRCPC

2019 Cholangiocarcinoma Foundation Annual Conference

The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by providing a forum to:

Knowledge

Increase knowledge central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma.

A New Perspective

Present a diversity of perspectives focused on clinical, basic, and translational research.

Stimulate

Stimulate multi-disciplinary, cross-institutional collaborations.

Innovation

Foster dialogue
and inspire innovation.

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons
  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies
  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma

Incredible Numbers from our 2018 Conference

Attendees

from 40 states and 12 countries representing healthcare, industry, patient advocacy organizations, patients, caregivers, academia and supporters.

Presentations

including those by researchers, surgeons, patients, caregivers and industry specialists.

Medical Institutions

represented, including international key opinion leaders advancing cholangiocarcinoma research, treatment and care.

Including

  • 190 patients/caregivers
  • 29 poster presentations
  • 786 webcast attendees

with support from

  • 30 organizations: ASLAN Pharmaceuticals, Agios, Amsety, ArQule, BTG, Bayer, Boston Scientific, Bristol-Myers Squibb, Conquer Cancer Foundation, doTERRA, Foundation Medicine, H3 Biomedicine, Halozyme, Incyte, Leap Therapeutics, Merck, Mundipharma, Nucana, PCI Biotech, PCORI, Perthera, Promotion in Motion, QED Therapeutics, RedHill Biopharma, Shire, Sirtex, Taiho Oncology, UPMC and Zymeworks.

Don't Wait, Be a Part of our 2019 Conference

2019-Box-1
2019-Box-2
2019-Box-3